Ipragliflozin

Appearance: White to off-white solid. Solubility: Soluble in DMSO, DMF or ethanol (all 20mg/ml). InChi Key: AHFWIQIYAXSLBA-RQXATKFSSA-N Smiles: FC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)=C2)=C2CC3=CC4=CC=CC=C4S3 Ipragliflozin is an orally active, highly potent sodium glucose co-transporter 2 (SGLT-2) inhibitor (IC50 = 7.4nM), selective over SGLT-1, 3, 4, 5 and 6. SGLT-2 is one subtype of SGLTs found almost exclusively in the proximal tubules of nephronic components in kidneys, playing a key role in the re-uptake of glucose in the proximal tubule of the kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Anti-diabetic and anti-obesity agent. Shown to improve glycemic control and reduce body weight, furthermore, lowering hypoglycemic risk and abdominal symptoms. SGLT-2 inhibitors are likely to improve beta-cell function and insulin sensitivity and restore glucose homeostasis. Attenuates non-alcoholic steatohepatitis (NASH) development. Product References Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo: A. Tahara, et al., Naunyn Schmiedebergs Arch. Pharmacol. 385, 423 (2012) Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus: M. Imamura, et al., Bioorg. Med. Chem. 20, 3263 (2012) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice: A. Tahara, et al., Eur. J. Pharmacol. 715, 246 (2013) Ameliorated pancreatic beta cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin: M. Takahara, et al., Endocr. J. 62, 77 (2015) Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus: T. Kawata, et al., J. Clin. Med. Res. 9, 586 (2017) In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor: T. Takasu, et al., Biol. Pharm. Bull. 42, 507 (2019) Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules: K. Hosokawa, et al., Int. J. Mol. Sci. 26, 190 (2019) SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation: S. Komatsu, et al., Endocr. J. 67, 99 (2020) Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model: A. Morishita, et al., PLoS One 17, e0261310 (2022)